Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Novel Combination Chemotherapy for Localized Ewing Sarcoma
(Posted: 03/22/2011) - In this clinical trial, researchers will test whether the addition of the drug combination vincristine, topotecan, and cyclophosphamide to a standard chemotherapy regimen improves overall survival and event-free survival in newly diagnosed patients with non-metastatic Ewing sarcoma of the bone or soft tissue (excluding the soft tissue of the skull).
- Optimizing Adjuvant Therapy for Resected Pancreatic Cancer
(Posted: 06/15/2010, Updated: 03/08/2011) - In this clinical trial, patients with resected pancreatic head cancer will be randomly assigned to receive either gemcitabine with or without erlotinib for 5 treatment cycles. Patients who do not experience disease progression or recurrence will then be randomly assigned to undergo an additional cycle of the same chemotherapy regimen with or without subsequent chemoradiation using either 5-FU or capecitabine.
- Treating Multiply Relapsed or Refractory Hairy Cell Leukemia
(Posted: 02/22/2011) - In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine.
- Dose-adjusted Chemotherapy for Untreated c-MYC-positive Lymphomas
(Posted: 01/25/2011) - In this trial, adult patients with newly diagnosed Burkitt lymphoma or c-MYC-positive diffuse large B-cell lymphoma will be separated into low-risk and high-risk groups; those in the low-risk group will be treated with at least three cycles of dose-adjusted EPOCH-R chemotherapy, while high-risk patients will receive six cycles.
- Combination Therapy for Advanced Kaposi Sarcoma
(Posted: 11/16/2010) - In this clinical trial, adult patients with any form of advanced Kaposi sarcoma will be treated with liposomal doxorubicin and bevacizumab every 3 weeks for a maximum of six treatments. Patients who respond to this therapy or have stable disease will receive bevacizumab alone every 3 weeks for a maximum of 11 treatments.